Mr Alsop added: "I am excited to be joining Hatchtech at such a crucial time for the company. It is clear that the attributes of DeOvo will deliver best-in-class benefits to patients, and thus a compelling commercial opportunity for the prospective marketers of the product. The next twelve months will require a dedicated and focused execution of the company's clinical, regulatory and commercial plans, and I look forward to leading this program to ensure the value of DeOvo is maximised for Hatchtech shareholders."

Hugh has over 16 years experience in the pharmaceutical industry and holds a Bachelor of Science with Honours (in Chemistry) from the University of Melbourne and an MBA from the Melbourne Business School.